The phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute myeloid leukemia (AML). We examined post-transplant outcomes and occurrence of hepatic veno-occlusive disease/sinusoidal obstruction...
-
February 9, 2021 (v1)Journal articleUploaded on: December 4, 2022
-
June 2020 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
July 1, 2024 (v1)Journal article
In this SFGM-TC registry study, we report the results after stem cell transplantation (HSCT) in 305 myelofibrosis patients, in order to determine potential risk factors associated with outcomes, especially regarding previous treatment with ruxolitinib. A total of 102 patients were transplanted from an HLA-matched-sibling donor (MSD), and 143...
Uploaded on: September 6, 2024 -
March 2017 (v1)Journal article
60-70% of AML patients have an indication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) during their treatment. Graft versus host disease (GvHD), the major cause of mortality and comorbidities post-transplantation, develops by immunological mechanism and decides greatly prognosis and quality of life (QoL) of graft recipient....
Uploaded on: February 28, 2023 -
November 15, 2022 (v1)Journal article
No description
Uploaded on: March 25, 2023